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Background: Predicting mortality in the intensive care unit (ICU) is one of the biggest challenges in critical care
medicine. Several studies have linked the presence of eosinopenia with adverse outcomes in different populations.
Methods: We performed a case control study to determine whether the eosinophil count at ICU admission was a
predictor of hospital mortality. We included data from patients 18 years or older admitted to the medical or surgical
ICU in a university hospital in northern of Mexico. Medical records of 86 non-survivors (cases) and 99 discharged
alive patients (controls) were randomly reviewed; clinical records of patients with an ICU stay of less than 24 h and
those whose information was incomplete were excluded.
Results: Median of eosinophil count at ICU admission was 0.013 (interquartile range (IQR) 0.00 to 0.57) K/μL. There
was no significant statistical difference in eosinophils at admission between survivors and non-survivors (0.014 [IQR
0.00 to 0.36] vs. 0.010 [IQR 0.00 to 0.57] K/μL, P = 0.35). In the multivariate analysis, APACHE II score at ICU admission
and discharge were the only mortality predictors. Survivors had a significantly greater increase in eosinophil count
during the first 7 days of ICU stay (0.104 [IQR −0.64 to 0.41] vs. 0.005 [IQR −1.79 to 0.43] K/μL, P = 0.004).
Conclusions: In our study, eosinophil count at ICU admission was not associated with increased hospital mortality.
The larger increase in number of eosinophils observed during the first week of ICU stay in surviving patients
deserves to be investigated further.
Keywords: Critical care, Eosinophils, Hospital mortalityBackground
Predicting mortality in the intensive care unit (ICU) is
one of the biggest challenges in critical care medicine.
A timely prognosis prediction is essential for proper decision-
making. There are several scales to quantify severity of critical
illness; most of them were validated in different popula-
tions, frequently in the context of clinical trials [1]. Al-
though there is continuous progress in prediction model
performance, their use in the individual patient should be
considered with caution given its poor sensitivity [2, 3]. In
order to achieve a better estimate of mortality, scales* Correspondence: jeglza111@gmail.com
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medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/based on biomarkers related to presence of oxidative stress
or systemic inflammatory response have been developed;
among the biomarkers most used in the ICU are C-
reactive protein, glucose, and lactate [4–7]. Several studies
have linked the presence of eosinopenia with increased
risk of death in patients with bacteremia [8], chronic ob-
structive pulmonary disease exacerbation [9], and in di-
verse populations admitted to the ICU [10–12]. The use
of eosinopenia as a prognostic factor at ICU admission is
attractive due to its availability, low cost, and minimum
delay between taking blood samples and obtaining results.
Its ease of application contrasts with complexity of various
scales and algorithms currently used. While the scales
with more clinical variables tend to show better perform-
ance compared to the simple ones [13], different bio-
markers have shown robust prognostic power even whenAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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of this study was to determine whether the eosinophil
count at ICU admission is a hospital mortality predictor.
Methods
Patients and context
We conducted a case control study using data from pa-
tients admitted to medical or surgical ICU from January
to September 2013. Our hospital is a teaching tertiary cen-
ter in northern Mexico; it has 23 intensive care beds:
13 for postoperative or trauma patients and 10 for pa-
tients with medical conditions. The study was approved
by the ethics committee of Dr. José E. González University
Hospital (registration number 14-004 NM).
Data collection
Medical records of non-survivors (cases) and discharged
alive patients (controls) were randomly reviewed. All pa-
tients were 18 years or older. For both groups, we collected
basic sociodemographic variables, diagnosis at ICU ad-
mission, daily eosinophil count during ICU stay, Acute
Physiology and Chronic Health Evaluation II (APACHE II)
score, Sequential Organ Failure Assessment (SOFA) scale
and in-hospital death. For patients with more than one
ICU admission or discharge, only the first event was in-
cluded. We excluded patients who had incomplete clinical
records or who were discharged to the general ward, trans-
ferred to another hospital or died within the first 24 h
since ICU admission. Blood sampling was performed by
the nursing staff, blood was collected through the prox-
imal port of a central venous catheter and placed in tubes
with ethylenediaminetetraacetic acid; the samples were
processed in a CELL-DYN Ruby System (Abbott Diagnostics,
Abbott Park, IL) in a central laboratory.
Statistical analysis
We estimated the sample size based in variable “eosino-
phil count at ICU admission” with the power.t.test func-
tion of the R commander (R program, version 2.1.2). We
calculated the standard deviation and corresponding mean
for survivors and non-survivors to evaluate difference ex-
tent and get the size of the effect. The number needed
to obtain a power of 80 % and 95 % confidence intervals
was 77 patients in each group. We tested normal distri-
bution with the Kolmogorov-Smirnov test. Data are shown
as means and standard deviations for variables with normal
distribution and as medians and interquartile ranges for
non-normal variables. We used the t test, the Mann–
Whitney U-test, ANOVA or chi-square as indicated. We
compared eosinophil count at admission between survi-
vors and non-survivors and also compared eosinophil
count at discharge and at third and seventh day in patients
who remained in ICU at those times. We calculated the
receiver operating characteristic (ROC) curve, area underthe curve (AUC) and Youden index for eosinophil at ICU
admission and compared it with AUC for APACHE II and
SOFA. According with sample size, we tested the eight
most significant variables in a multivariate analysis by the
Cox proportional regression model; the multicollinear-
ity between predictor variables was ruled out by introdu-
cing at multivariate analysis only those with Pearson
correlation coefficient less than .80. We defined a statisti-
cally significant difference as a P value less than .05. Ana-
lysis was performed using SPSS version 18.0 for Windows
(SPSS Inc., Chicago, IL).
Results
During the study period, 735 patients were admitted at
medical or surgical ICU and 179 (24.3 %) died. We in-
cluded data of 185 patients, 99 (53.3 %) in the survivors
group and 86 (46.5 %) in the non-survivors group. Clinical
and demographic characteristics are shown in Table 1.
Mean age was 47 ± 18 years. Male sex was predominant.
The most common cause of ICU admission was a medical
disease (47 %). Eighty-six patients had diagnostic criteria for
sepsis, 27 (27.3 %) in the survivors and 59 (68.6 %) in the
non-survivors group (P < .001). Time and cause of death
are shown in Table 2. Main mortality cause was septic
shock in 53.5 % of patients. Fifty-six (65.1 %) patients died
from the disease that caused their admission.
Eosinophil count median at ICU admission was 0.013
(interquartile range (IQR) 0.00 to 0.57) K/μL. There was
no statistically significant difference in admission eosino-
phils between survivor and non-survivor patients (0.014
[IQR 0.00 to 0.36] vs. 0.010 [IQR 0.00 to 0.57] K/μL, P =
0.35). In the 86 patients with sepsis, eosinophil count at
admission was not different between survivors and non-
survivors (0.013 [IQR 0.00 to 0.05] vs. 0.016 [IQR 0.00
to 0.06] K/μL, P = 0.44). Taking as a cutoff point, the
traditional level of 0.40 K/μL, 126 (67.6 %) patients pre-
sented eosinopenia at ICU admission, difference between
groups was not significant (64 [64.6 %] vs. 61 [70.9 %],
P = 0.36).
In univariate analysis the following factors were associ-
ated with hospital mortality: age, APACHE II and SOFA
at ICU admission and discharge, sepsis, eosinophil count
at ICU discharge, type 2 diabetes mellitus, chronic kidney
disease, solid neoplasia, a medical diagnosis as admission
cause, and discharge to the general ward during a night
shift. Eosinophil count at 72 h showed borderline signifi-
cance (0.13 [IQR 0.0 to 0.90] vs. 0.040 [0.0 to 0.76] K/μL,
P = .05). ICU stay was 2.5 days longer in the group of non-
survivors (5 [IQR 1 to 28] vs. 7.5 [IQR 1 to 46] days, P =
0.004). The total hospital stay was shorter in non-survivor
group (18 [IQR 3 to 96] vs. 11.5 [2 to 56] days, P = 0.007).
Patients with elective surgery had a lower mortality (21
[21.2 %] vs. 4 [4.7 %], P = 0.001). Seventy-four (74.7 %)
survivors and 45 (52.3 %) non-survivor patients remained
Table 1 Clinical and demographic variables at ICU admission
Variable Total Survivors Non-survivors P value
Patients 185 (100.0) 99 (53.5) 86 (46.5)
Age, years 47 (18.2) 43 (17.4) 51 (18.3) 0.003
Men 128 (69.2) 74 (74.7) 54 (62.8) 0.079
APACHE II, score 16 (1–37) 12 (1–30) 21 (9–37) <0.001
SOFA, score 6 (0–20) 5 (0–14) 9 (2–20) <0.001
Predicted mortality, % 25 (4–85) 15 (4–75) 40 (9–85) <0.001
Comorbidities
DM2 58 (31.4) 23 (23.2) 35 (40.7) 0.011
Ischemic cardiopathy 24 (13.0) 12 (12.1) 12 (14.0) 0.711
Chronic nephropathy 23 (12.4) 5 (5.1) 18 (20.9) 0.001
Chronic liver disease 7 (3.8) 2 (2.0) 5 (5.8) 0.265
Chronic pneumopathy 7 (3.8) 4 (4.0) 3 (3.5) 1.000
Blood neoplasia 1 (0.5) 1 (1.0) 0 (0.0) 1.000
Solid neoplasia 15 (8.1) 4 (4.4) 11 (12.8) 0.030
HIV infection 5 (2.7) 1 (1.0) 4 (4.7) 0.285
ICU admission diagnosis
Medical 87 (47.0) 37 (37.4) 50 (58.1) 0.005
Surgical, urgent 40 (21.6) 19 (19.2) 21 (24.4) 0.389
Surgical, elective 25 (13.5) 21 (21.2) 4 (4.7) 0.001
Trauma 33 (17.8) 22 (22.2) 11 (12.8) 0.095
ICU admission eosinophils count, K/μL 0.013 (0.0–0.578) 0.014 (0.0–0.363) 0.010 (0.0–0.578) 0.355
Hospital stay, days 14 (2–96) 18 (3–96) 11.5 (2–56) 0.007
ICU stay, days 6 (1–46) 5 (1–28) 7.5 (1–46) 0.004
Data are shown as number and percentage, mean and standard deviation or median and interquartile range as needed
ICU intensive care unit, APACHE II acute physiology and chronic health evaluation II, SOFA sequential organ failure assessment score, DM2 type 2 diabetes mellitus,
HIV human immunodeficiency virus
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nificantly greater increase in eosinophil count during the
first 7 days of ICU stay (0.104 [IQR −0.64 to 0.41] vs. 0.005
[IQR −1.79 to 0.43] K/μL, P = 0.004).
The AUC for eosinophil count at admission, APACHE
II and SOFA was 0.53 (IQR 0.45 to 0.62), 0.83 (IQR 0.77
to 0.89), and 0.78 (IQR 0.71 to 0.84), respectively.Table 2 Time and death cause in non-survivors group
Cause of death Day 1 to 7 Day 8 to 14 Day
Cancer 1




Respiratory insufficiency 5 5 1
Septic shock 17 15 7
Total, n (%) 41 (47.7) 22 (25.6) 8 (9
Death causes are shown as number; total data are shown as number and percentagThe results of the multivariate analysis are shown in
Table 3. Only APACHE II score at admission and at dis-
charge significantly predicted hospital mortality.
Discussion
Eosinophils are pleiotropic, multifunctional cells involved








.3) 6 (7.0) 9 (10.5) 86 (100.0)
e
Table 3 Factors associated with hospital mortality, multivariate
analysis
Variable HR 95 % CI P value
Age 0.994 0.97–1.00 0.407
APACHE II at admission 1.039 1.00–1.07 0.048
APACHE II at ICU discharge 1.097 1.06–1.13 <0.001
Hospital stay 0.805 0.75–0.85 <0.001
Eosinophils <0.10 K/μL at 72 h 1.333 0.76–2.32 0.312
Eosinophils <0.03 K/μL at ICU discharge 0.965 0.54–1.70 0.903
Discharge from ICU during night shift 1.165 0.66–2.03 0.591
Medical diagnosis at ICU admission 1.342 0.80–2.23 0.259
HR hazard ratio, CI confidence interval, APACHE II acute physiology and chronic
health evaluation II, SOFA sequential organ failure assessment score, ICU
intensive care unit, DM2 type 2 diabetes mellitus
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regulated by granulocyte colony-stimulating factor, macro-
phages, IL-3, and IL-5; decrease in their concentration, as
occurs during bacterial or fungal sepsis [18], causes eosino-
phil apoptosis after 48 to 72 h [17, 19]. In 1893, Zappert
first described the reduction in eosinophil count related to
acute infection [20]. It has been proposed that this de-
crease is due to at least three mechanisms: 1) peripheral
sequestration in inflamed tissue, 2) eosinophils produc-
tion inhibition, and 3) suppression of mature cell release
from the bone marrow [10]. In animal model, there is
an up to 80 % reduction in eosinophil count within
6 h after the infective stimulus [21]. Several studies have
proposed eosinopenia as a marker for infection [22–28];
in contrast, eosinophilia is infrequent during severe sep-
sis, and its presence even leads to questioning the infec-
tious etiology of the systemic inflammatory response
syndrome [29].
Eosinopenia is frequent and has been linked to mortality
in different settings during critical illness; in our study, it
was present in 67.5 % of patients, an intermediate value
compared to 46.5 % and 86 %, reported by Ho et al. in
critically ill patients with bacteremia [7, 28]. We did not
find an association between eosinophil count at ICU ad-
mission and hospital mortality, this contrast with that re-
ported by other authors [10, 12, 30]. The retrospective
design of our study, including an unselected population of
critically ill patients and increased frequency of sepsis in
the group of non-survivors, could explain this difference.
We did not find a difference in eosinophil count at ICU
admission between survivor and non-survivor patients
with sepsis; the value of this analysis is limited due to a
low number of included patients.
In univariate analysis, eosinophil count at 72 h showed
borderline significance to predict hospital mortality (0.13
[IQR 0.0 to 0.90] vs. 0.040 [IQR 0.0 to 0.76] K/μL, P =
0.05); we build ROC curve and identified 0.103 K/μL ascount with a greater discrimination power. However, at
multivariate analysis this did not remain as an independent
predictor of hospital mortality. Bass et al. found that circu-
lating eosinophil number increases as early as 12 h after
appropriate antibiotic treatment initiation [21]. Even
though there is no evidence to support the 72 h as a spe-
cific point in time at which increase in eosinophil count
relates to better outcomes, we arbitrarily defined a 72-h
period based on theory that serial measurement of this
biomarker could resemble the serial measurement of other
markers along evolution of critical illness (e.g., procalcito-
nin); our results did not support this hypothesis.
A retrospective study of 1446 patients demonstrates
that an eosinophil count <0.01 K/μL at ICU discharge is
associated with an increased risk of readmission (HR
2.50 [95 % CI 1.38 to 4.50], P = 0.002) and hospital mor-
tality (HR 2.65 [95 % CI 1.77 to 3.98], P = 0.001) [11].
Our ROC curve analysis placed that point in 0.031 k/μL.
Given that up to 10 % of patients discharged from the
ICU die before leaving the hospital [31], various scales
have been developed to reduce the number of inad-
equate discharges from the ICU [32–34], but their use is
frequently limited due to their complexity. In this regard,
eosinopenia is an interesting marker: it may reflect a state
of persistent inflammatory response, where the action of
various cytokines avoids normalization of eosinophil count.
However, in multivariate analysis of our data, eosinophils
at ICU discharge were not significant predictors of hospital
mortality; lack of significance at multivariate analysis could
be due to the low number of patients since the sample size
was not calculated for this outcome.
Consistent with the available literature [8, 10, 30], we
found that the inability to increase the eosinophil count
was a predictor of mortality. In our study, survivors showed
a 20-fold increase in the eosinophil count at the seventh
day compared to non-survivors. The increase in eosinophil
number during the first week of ICU stay in patients who
survived is a valuable result given the biological context that
relates their presence with the resolution of the inflamma-
tory state [7, 21]. This aspect becomes even more valuable
given the easy access and low cost of blood cells count.
Our study has several limitations. First, its retrospect-
ive design involved a limited value in the quality of in-
formation; in addition, the background of comparative
groups was different and potentially included several un-
determined confounding factors. Second, we did not
take into account the percentage of eosinophils with re-
spect to total leukocyte count; this factor was related to
an increase in predictive power, sensitivity, and AUC for
mortality prediction in one study [12]. Third, patients
were not stratified according to steroids or vasoactive
amines use; these substances have been associated with
eosinophils apoptosis [19]. Finally, the study was con-
ducted at a single center.
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In this study, the eosinophil count at admission to the
ICU was not associated with increased in hospital mor-
tality. In our population, the APACHE II score at ICU
admission and discharge remains as the best mortality
predictors. The larger increase in eosinophil number
during the first 7 days of ICU stay observed in survivor
patients is a finding that deserves to be investigated in
future studies.
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